Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Total Non-Current Liabilities (2020 - 2023)

Historic Total Non-Current Liabilities for Evoke Pharma (EVOK) over the last 4 years, with Q4 2023 value amounting to $6.6 million.

  • Evoke Pharma's Total Non-Current Liabilities rose 818.02% to $6.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $6.6 million, marking a year-over-year increase of 818.02%. This contributed to the annual value of $6.6 million for FY2023, which is 818.02% up from last year.
  • According to the latest figures from Q4 2023, Evoke Pharma's Total Non-Current Liabilities is $6.6 million, which was up 818.02% from -$6.5 million recorded in Q3 2023.
  • In the past 5 years, Evoke Pharma's Total Non-Current Liabilities ranged from a high of $6.6 million in Q4 2023 and a low of -$6.5 million during Q3 2023
  • For the 4-year period, Evoke Pharma's Total Non-Current Liabilities averaged around $3.8 million, with its median value being $5.5 million (2021).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 16723.11% in 2021, then plummeted by 20853.21% in 2023.
  • Evoke Pharma's Total Non-Current Liabilities (Quarter) stood at $5.1 million in 2020, then increased by 9.77% to $5.6 million in 2021, then increased by 8.91% to $6.1 million in 2022, then increased by 8.18% to $6.6 million in 2023.
  • Its last three reported values are $6.6 million in Q4 2023, -$6.5 million for Q3 2023, and -$6.4 million during Q2 2023.